PRF Technologies (PRFX) Capital Expenditures (2021 - 2024)

PRF Technologies (PRFX) recorded quarterly Capital Expenditures of -$5000.0 in Q2 2024, up 28.57% on a QoQ basis from -$7000.0 in Q1 2024.

PRF Technologies (PRFX) Capital Expenditures (2021 - 2024) Analysis & Trends

PRF Technologies has disclosed Capital Expenditures across 3 years of filings, most recently posting -$5000.0 for Q2 2024.

Quarterly Capital Expenditures changed N/A year-over-year to -$5000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was -$3000.0 (changed N/A YoY) and the FY2025 annual result came in at $2000.0, down 84.62% from the prior year.
Capital Expenditures climbed to -$5000.0 in Q2 2024, from -$7000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $72000.0 in Q4 2021 and troughed at -$13000.0 in Q1 2021.
A 3-year average of $5875.0 and a median of -$5500.0 in 2021 frame the typical range for Capital Expenditures.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	168.00 Mn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	110.00 Mn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	100.80 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	9.10 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	51.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	4.09 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	8.83 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	2.04 Mn
10	PRF Technologies	933,081.16	-2.46 Mn	-	-

Download Data